Silexion Therapeutics Ltd.
SLXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $188,090 | $294,119 | $4,403,585 | $4,345,086 |
| - Cash | $1,187 | $4,595 | $8,259 | $39 |
| + Debt | $4,491 | $171 | $271 | $0 |
| Enterprise Value | $191,394 | $289,695 | $4,395,597 | $4,345,047 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16,477 | -$4,636 | -$3,803 | -$755 |
| % Margin | – | – | – | – |
| Net Income | -$16,443 | -$4,942 | -$3,215 | -$755 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.64 | -4.42 | 0.035 | -0.046 |
| % Growth | 40.3% | -12,764.8% | 176.2% | – |
| Operating Cash Flow | -$8,396 | -$4,529 | -$3,335 | -$1,407 |
| Capital Expenditures | -$22 | -$12 | -$40 | -$0 |
| Free Cash Flow | -$8,418 | -$4,541 | -$3,375 | -$1,407 |